Search clinical trials for: moderate psoriasis

Total 7633 results

Jinnah Postgraduate Medical Centre

Completed

Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Plaque Psoriasis

Pakistan
Amgen

Completed

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. (UNVEIL)

Parapsoriasis

United States
Samsung Bioepis Co., Ltd.
Organon and Co

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Czechia, Lithuania, Poland, Bulgaria
Novartis Pharmaceuticals

Completed

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (METABOLYX)

Psoriasis | Metabolic Syndrome

Germany
Syntrix Biosystems, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Psoriasis

United States
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Completed

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Thailand
Novartis Pharmaceuticals

Completed

A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting

Moderate-to-severe Plaque Psoriasis

Indonesia
Eli Lilly and Company

Terminated

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Germany, Australia, Italy, Israel, Poland, Japan, Argentina, Hungary, Taiwan, United Kingdom, Mexico, Czechia, Russian Federation
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (TRIBUTE)

Plaque Psoriasis

Spain, Italy
Akeso
Akeso Tiancheng, Inc

Completed

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Akeso

Completed

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

Psoriasis

China
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (GENESIS)

Dermatitis, Atopic

United States, Germany, Canada, Poland, Japan
LEO Pharma

Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2)

Atopic Dermatitis

United States, Denmark, United Kingdom, Korea, Republic of, Canada, Italy, Australia, Poland, Russian Federation
Bioeq GmbH

Completed

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

Plaque Psoriasis

Poland, Estonia, Ukraine, Georgia
Sanofi

Completed

A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

Psoriasis

Germany
AbbVie

Completed

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Hidradenitis Suppurativa (HS)

United States, Canada, Japan, Puerto Rico
Alvotech Swiss AG

Completed

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Psoriasis

Georgia, Estonia, Poland, Ukraine
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
University Hospitals Cleveland Medical Center

Completed

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

Plaque Psoriasis

United States
Actelion

Completed

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Hungary, Italy, Lithuania, Romania, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-2)

Psoriasis

United States, Spain, Hungary, Australia, Germany, Canada, Czechia, Poland, Puerto Rico, Finland, France, Israel, Italy, New Zealand, Sweden, United Kingdom
Evelo Biosciences, Inc.

Completed

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom, Hungary, Poland, United States
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Active, not recruiting

A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Psoriasis

China
AbbVie

Completed

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Brazil
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Psoriasis

Japan
Evelo Biosciences, Inc.

Completed

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Psoriasis | Asthma | Atopic Dermatitis

United Kingdom
Biocool AB

Completed

Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

Plaque Psoriasis

Sweden
Galderma R&D

Completed

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

Scalp Psoriasis

United States
Akeso

Completed

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Psoriasis

China
Lipidor AB
Bioskin GmbH

Completed

Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis (AKVANO-AKP01)

Psoriasis Vulgaris

Germany
Arcutis Biotherapeutics, Inc.

Completed

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Psoriasis

Canada, United States
Galderma R&D

Completed

Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

Plaque Psoriasis

United States, Canada
University of Michigan

Completed

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

Psoriasis

United States
Boehringer Ingelheim

Completed

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States
Can-Fite BioPharma

Completed

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

Israel, Serbia, Romania, Croatia, Bosnia and Herzegovina, Bulgaria, Canada, Moldova, Republic of, Poland
Bristol-Myers Squibb

Completed

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (DCE)

Psoriasis

United States
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

Plaque Psoriasis

United Kingdom, Germany
Eli Lilly and Company
Dermira, Inc.

Completed

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

Atopic Dermatitis

United States, Canada, Germany, Poland
Shanghai Henlius Biotech

Completed

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Alvotech Swiss AG

Completed

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Poland, Georgia, Iceland, Russian Federation, Ukraine
Dr. Reddy's Laboratories Limited
XenoPort, Inc.

Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Psoriasis

United States
Saakshi Khattri

Completed

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Psoriasis

United States

3

Subscribe